SCR 81 is a New Jersey concurrent resolution requesting the U.S. President and Congress to amend federal Medicaid rules to permit federal funding for substance use disorder treatment programs currently excluded under the "IMD exclusion." This exclusion prevents Medicaid reimbursement for inpatient and outpatient treatment in facilities classified as Institutions for Mental Diseases (IMDs), forcing states to cover full costs. The resolution seeks to repeal or modify this exclusion - allowing states like New Jersey to use federal Medicaid funds for these programs - thereby reducing state financial burdens and expanding access to treatment for individuals with substance use disorders.
This bill exempts from motor vehicle registration fees certain vehicles owned by local senior nutrition programs (specifically Meals on Wheels America members) and nonprofit organizations providing social services in New Jersey, such as addiction support or mental health services. The exemption applies to vehicles not used for pleasure or hire, requiring them to still be registered with standard or special number plates valid for up to 26 months. Owners may transfer the special registration to a new vehicle by applying to the chief administrator, maintaining compliance without fee payments.
New Jersey bill A 1775 requires health insurers (including hospital, medical, and health service corporations) to cover counseling and behavioral therapies for anyone receiving medication-assisted treatment (MAT) for opioid addiction. The bill mandates that this coverage be provided under the same terms and conditions as other medical treatments, prohibiting stricter limits on mental health/substance use disorder benefits compared to general medical care. It directly affects insured individuals seeking treatment for substance use disorders and requires insurers to comply with federal mental health parity standards. The law would apply to all health insurance contracts issued or renewed in New Jersey after its effective date.
New Jersey's A 2434 establishes a 26-member Behavioral Health Services Task Force within the Department of Human Services. The task force will study mental health and substance use disorder services county by county, identify gaps in care for children, adults, and emergency access, and make recommendations to improve service coordination, funding use, and program expansion. It must report findings and specific actionable steps to the Governor and Legislature within 18 months of the bill's effective date, after which the task force will dissolve. This bill directly affects all New Jersey residents seeking behavioral health services by initiating a state-level review process to address system weaknesses.
This bill requires New Jersey counties to appoint a pretrial release coordinator for defendants charged with serious offenses (indictable or disorderly persons) who are released before trial. The coordinator evaluates each defendant's needs and voluntarily connects them to services like substance abuse treatment, food assistance (SNAP), Medicaid, housing aid, job training (Work First NJ), and insurance applications. Counties must track which defendants access these services, along with demographic data and any subsequent arrests, and submit annual reports to the Governor and Legislature. The bill directly affects defendants on pretrial release and aims to improve access to supportive services during their court process.
This New Jersey bill requires general acute care hospitals to include fentanyl testing in urine drug screenings used to diagnose patient conditions. It directly affects hospitals conducting such screenings, mandating they test for fentanyl - a highly potent synthetic opioid often mixed with other drugs like cocaine or heroin, contributing to overdose deaths. The key provision adds fentanyl to standard screening panels, which currently test for substances like cocaine and other opioids but not fentanyl. The law takes effect immediately but expires on January 1, 2028.
New Jersey's bill A 2378 establishes a three-year Remote Methadone Dosing Pilot Program to test whether telehealth can improve opioid treatment. It selects one opioid treatment program each in Atlantic City, Camden, and Paterson to offer remote methadone dosing via approved telehealth technology, allowing eligible patients to receive take-home doses with remote monitoring when clinically appropriate. Participating programs must report annually on patient outcomes (like treatment compliance and retention) and cost savings (such as reduced transportation costs), with the state requiring a final report within four years to evaluate expansion potential. The bill appropriates $225,000 total ($75,000 per program) to fund the pilot and support participating opioid treatment programs.
This bill establishes new rules for prescribing and dispensing benzodiazepines (like Xanax and Valium) and similar sleep medications (like Ambien). It requires healthcare providers to give patients a detailed pamphlet about risks, obtain signed consent, and use bold labels warning of addiction risks. Prescriptions for these drugs cannot exceed four weeks without medical justification, and providers must follow safe tapering protocols to help patients reduce use gradually. The rules apply to most patients but exclude those receiving care in long-term facilities like nursing homes.
This bill (A 538, "Pharmaceutical Representative Licensing Act") requires all individuals marketing pharmaceuticals to healthcare practitioners in New Jersey to obtain a state license. It directly affects pharmaceutical sales representatives, who must meet education, ethics, and background requirements, complete biennial continuing education (including opioid safety training), and report all interactions with doctors - including promoted drugs, samples given, and gifts provided. The State Board of Medical Examiners will oversee licensing, enforce standards (like banning deceptive marketing or false medical credentials), and may suspend licenses for violations. The bill aims to increase transparency and professionalism in pharmaceutical sales interactions.
This New Jersey bill (A 449) requires all colleges and universities to place automatic external defibrillators (AEDs) in unlocked locations within athletic facilities and student centers, accessible during normal operating hours. It also mandates that institutions maintain a supply of naloxone nasal spray near each AED for opioid overdose emergencies, with designated staff trained to use both devices. Institutions must ensure at least two staff members are CPR- and AED-trained during facility hours and regularly test/maintain equipment, while also designating a campus medical professional to oversee naloxone use. The bill provides liability protection for institutions and staff acting in good faith when implementing these requirements.
